Who are Naltrexone Tablet and Nicotine Patch's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/naltrexone-tablet-and-nicotine-patch.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Naltrexone Tablet and Nicotine Patch — Competitive Intelligence Brief

Naltrexone Tablet and Nicotine Patch (Naltrexone Tablet and Nicotine Patch) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid antagonist + nicotine replacement therapy combination. Area: Addiction Medicine / Smoking Cessation.

marketed Opioid antagonist + nicotine replacement therapy combination Mu-opioid receptor (naltrexone); nicotinic acetylcholine receptors (nicotine) Addiction Medicine / Smoking Cessation Small molecule Live · refreshed every 30 min

Target snapshot

Naltrexone Tablet and Nicotine Patch (Naltrexone Tablet and Nicotine Patch) — The Scripps Research Institute. This combination uses naltrexone to block opioid receptors and reduce cravings while nicotine patch provides nicotine replacement to support smoking cessation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Naltrexone Tablet and Nicotine Patch TARGET	Naltrexone Tablet and Nicotine Patch	The Scripps Research Institute	marketed	Opioid antagonist + nicotine replacement therapy combination	Mu-opioid receptor (naltrexone); nicotinic acetylcholine receptors (nicotine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid antagonist + nicotine replacement therapy combination class)

The Scripps Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Naltrexone Tablet and Nicotine Patch — Competitive Intelligence Brief. https://druglandscape.com/ci/naltrexone-tablet-and-nicotine-patch. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab